|Title||The Return of Actionable Variants Empirical (RAVE) Study, a Mayo Clinic Genomic Medicine Implementation Study: Design and Initial Results.|
|Publication Type||Journal Article|
|Year of Publication||2018|
|Authors||Kullo, IJ, Olson, J, Fan, X, Jose, M, Safarova, M, Breitkopf, CRadecki, Winkler, E, Kochan, DC, Snipes, S, Pacyna, JE, Carney, M, Chute, CG, Gupta, J, Jose, S, Venner, E, Murugan, M, Jiang, Y, Zordok, M, Farwati, M, Philogene, M, Smith, E, Shaibi, GQ, Caraballo, P, Freimuth, R, Lindor, NM, Sharp, R, Thibodeau, SN|
|Journal||Mayo Clin Proc|
|Date Published||2018 Nov|
OBJECTIVES: To identify clinically actionable genetic variants from targeted sequencing of 68 disease-related genes, estimate their penetrance, and assess the impact of disclosing results to participants and providers.
PATIENTS AND METHODS: The Return of Actionable Variants Empirical (RAVE) Study investigates outcomes following the return of pathogenic/likely pathogenic (P/LP) variants in 68 disease-related genes. The study was initiated in December 2016 and is ongoing. Targeted sequencing was performed in 2533 individuals with hyperlipidemia or colon polyps. The electronic health records (EHRs) of participants carrying P/LP variants in 36 cardiovascular disease (CVD) genes were manually reviewed to ascertain the presence of relevant traits. Clinical outcomes, health care utilization, family communication, and ethical and psychosocial implications of disclosure of genomic results are being assessed by surveys, telephone interviews, and EHR review.
RESULTS: Of 29,208 variants in the 68 genes, 1915 were rare (frequency
CONCLUSION: Expected traits were present in 13% of participants with P/LP variants in non-FH CVD genes, suggesting low penetrance; this estimate may change with additional testing performed as part of the clinical evaluation. Ongoing analyses of the RAVE Study will inform best practices for genomic medicine.
|Alternate Journal||Mayo Clin. Proc.|